Related Experiment Video
Updated: Jul 18, 2026
05:19
Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
Seligiline transdermal system in depression.
1Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Carrier Clinic, POB 147, 252 CR 601, Belle Mead, NJ 08502, USA. pgoodnick@aol.com
Expert Opinion on Pharmacotherapy
|December 14, 2006
Summary
Selegiline transdermal system offers an effective daily treatment for major depressive disorder, with the 6 mg/24h dose showing safety and efficacy without dietary restrictions. Continued treatment demonstrated significant benefits over 52 weeks.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Selegiline, a monoamine oxidase inhibitor, is FDA-approved for Parkinson's disease.
- Transdermal selegiline demonstrates efficacy for major depressive disorder (MDD).
Purpose of the Study:
- To evaluate the efficacy and safety of daily transdermal selegiline for MDD treatment.
- To assess required dietary precautions and potential drug interactions.
Main Methods:
- Two clinical trials assessed selegiline dosages (6, 9, 12 mg/24h).
- A 52-week randomized prevention study evaluated treatment continuation.
- Tyramine challenge studies and safety data analysis were conducted.
Main Results:
- The 6 mg/24h dose was effective and did not require dietary precautions.
- Higher doses showed potential for similar safety, but data is limited.
- No hypertensive crises were reported; tyramine studies indicated a safety margin.
- Common side effects included orthostatic hypotension and insomnia; application site reactions were frequent.
- Contraindicated drugs include SSRIs, SNRIs, and certain analgesics due to serotonin syndrome risk.
Conclusions:
- Transdermal selegiline is a viable daily treatment for MDD, particularly the 6 mg/24h dose.
- Careful management of drug interactions is crucial, requiring medication cessation periods before and after treatment.
- Long-term treatment appears beneficial and safe with appropriate monitoring.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...